GlobalData on MSN6mon
FDA shuns Rocket’s immune disorder gene therapy over manufacturing shortcomings
The US Food and Drug Administration (FDA) has declined to approve Rocket Pharmaceutical’s Kresladi (marne-cel), requesting ...
circuitdigest.com4d
AI Meets Rocketry: A Self-Learning Neural Network For Thrust Vector Control
A fully self-training, neural network-based thrust vector control (TVC) system that promises smarter and more efficient ...
SpaceX’s holiday greetings involve a quirky rocket-engine nozzle dance
SpaceX has offered holiday greetings via a spot of synchronized rocket-engine nozzle steering. The quirky 65-second video — ...
Promising Pipeline and Strategic Developments Propel Rocket Pharmaceuticals to ‘Buy’ Rating
Yun Zhong, an analyst from Wedbush, has initiated a new Buy rating on Rocket Pharmaceuticals (RCKT).Don't Miss Our New Year's Offers:Discover ...
Hackaday3y
Three-Stage Thrust Vectoring Model Rocket With Tiny Flight Computers
Flying a thrust-vectoring rocket can be a challenge, and even more so if you stack multiple stages and a minimalist flight computer on top of it all. But [Joe Barnard] is not one to shy away from ...
CNN1y
Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals ... Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based ...
Business Wire1mon
Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference
Rocket’s lentiviral (LV) vector-based hematology portfolio consists of late-stage programs for Fanconi Anemia (FA), a difficult-to-treat genetic disease that leads to bone marrow failure (BMF ...
Business Wire1mon
Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
Rocket’s lentiviral (LV) vector-based hematology portfolio consists of late-stage programs for Fanconi Anemia (FA), a difficult-to-treat genetic disease that leads to bone marrow failure (BMF ...